The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma ...

Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, ...

Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology ...

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial ...

Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from ...

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux debuted a “double-masked” T cell engager.

Patients who'd seen substantial hair regrowth in the first part of Nektar’s trial had a "deepening" treatment response, ...

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...

Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve ...